Concurrent use of hormonal long-acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013-2021

Simple item page
dc.contributor.authorBoyce, A.E.
dc.contributor.authorCaccetta, T.
dc.contributor.authorSee, J.-A.
dc.contributor.authorNixon Am, R.L.
dc.date.issued2025
dc.descriptionAvailable online 24 September 2025. Letter to the Editor.
dc.description.abstractAbstract is not available.
dc.description.statementofresponsibilityAaron E. Boyce, Tony Caccetta, Jo-Ann See, Rosemary L. Nixon AM
dc.identifier.citationMedical Journal of Australia, 2025; 223(8):439-439
dc.identifier.doi10.5694/mja2.70058
dc.identifier.issn0025-729X
dc.identifier.issn1326-5377
dc.identifier.urihttps://hdl.handle.net/2440/147704
dc.language.isoen
dc.publisherWiley
dc.rights© 2025 AMPCo Pty Ltd.
dc.source.urihttps://doi.org/10.5694/mja2.70058
dc.subjectPrescription drugs; Contraception; Patient safety
dc.titleConcurrent use of hormonal long-acting reversible contraception by women of reproductive age dispensed teratogenic medications, Australia, 2013-2021
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Research Outputs